Key Findings

• Current U.S. clinical guidelines endorse puberty blockers, cross-sex hormones, and surgery for youth gender dysphoria, but international bodies in England, Sweden, and Finland have pulled back after systematic reviews found weak evidence of medical benefits.
• The Dutch protocol—the original research basis for pediatric medical transition—had significant methodological flaws, including no control group, confounded measurement of gender dysphoria, and a population very different from today's patients.
• Some bioethicists argue youth should have a right to transition-related interventions based on 'embodiment goals' and autonomy alone, without requiring evidence of mental health benefits or even a diagnosis.
• The author argues this autonomy-based view contradicts medicine's core principle of nonmaleficence: patient desire for body modification is not sufficient justification for risky medical interventions without evidence of health benefits.
• International discrepancies in treatment guidelines stem partly from different standards of evidence assessment (systematic reviews vs. narrative reviews) and partly from deeper value disagreements about whether medicine's aim is health improvement or fulfilling patient identity goals.

Abstract

The original “Dutch Protocol”—the treatment model comprised of puberty blockers, cross-sex hormones, and surgery—was intended to improve the mental and physical health of pediatric patients experiencing distress over their sexed bodies. Consequently, both researchers and clinicians have couched eligibility for treatment and measures of treatment efficacy in terms of the interventions’ effects on outcomes such as gender dysphoria, depression, anxiety, and suicide. However, recent systematic reviews have concluded that the scientific evidence supporting these interventions is uncertain, leading to significant international differences in what treatments are offered to youth. Against this backdrop, a different argumentative approach has emerged in support of gender-affirming care. This approach appeals not to reductions in patient morbidity or mortality but to patient autonomy, where medical intervention is pursued as a means to the satisfaction of a patient's “embodiment goals.” In this article, I raise objections to autonomy-based justifications for pediatric gender-affirming care, concluding that these arguments misunderstand the place of autonomy in clinical decision-making and, consequently, put patients at risk of medical harm.

Summary

This paper examines competing justifications for gender-affirming medical interventions (puberty blockers, cross-sex hormones, and surgery) in youth, contrasting the traditional mental health-based rationale with newer autonomy-based arguments that prioritize patients' embodiment goals regardless of diagnostic criteria. The author argues that the autonomy-based view—exemplified by bioethicist Florence Ashley's defense of diagnosis-free, identity-driven medical transition—represents a dangerous departure from medicine's foundational commitment to nonmaleficence, and that such interventions should only be provided when there is strong evidence of measurable health benefits. The paper critiques methodological limitations in foundational Dutch studies, analyzes international discrepancies in treatment guidelines, and contends that patient autonomy in medicine properly functions as a right to refuse or choose among clinically justified options, not as a basis to demand any desired intervention irrespective of risk-benefit profiles.

Conclusion

This article argues that the autonomy-based view—according to which medical interventions for gender dysphoria in youth ought to be guided by patients' embodiment goals rather than measurable health outcomes—is misguided, as it conflicts with medicine's long-standing commitment to nonmaleficence. The author contends that transition-related medical treatments for youth are justified only if there is good evidence of a favorable risk-benefit profile in terms of measurable health outcomes; an adolescent's desire to obtain particular sex characteristics is not sufficient to establish a right to such interventions. The author critiques consequentialist arguments (including those appealing to gender euphoria, creative transfiguration, dehumanization, and social marginalization) and autonomy-based arguments (including the right to an open future and an analogy to reproductive healthcare), finding them all insufficient to justify departure from the traditional medical aim of protecting and promoting patient health. The practical upshot is that, absent compelling reasons to abandon this commitment, the medical profession should reaffirm that serious medical interventions require strong evidence of a favorable risk-benefit profile for treating physical and psychiatric morbidity and relieving suffering. The author acknowledges the limitation that this article is largely negative and does not fully articulate a positive philosophical account of health or the aims of medicine, but hopes to have surfaced conceptual and moral tensions in contemporary pediatric gender medicine.